Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214530 | 0.86 | EDNRA (0.42) | ESR1KDM4EMAPTNPSR1 | |
| SCHEMBL5215532 | 0.86 | EDNRA (0.44) | ESR1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4762793 | 0.85 | ESR1 (0.43) | ESR1 | |
| SCHEMBL5215280 | 0.85 | ESR1 (0.43) | ESR1KDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL4770247 | 0.85 | ESR1 (0.38) | ESR1AKR1C3MAPTNPSR1RXFP1 | |
| SCHEMBL5766360 | 0.84 | MAP3K8 (0.42) | ESR1 | |
| SCHEMBL5212261 | 0.84 | MEN1 (0.43) | AKR1C3KDM4EALDH1A1MAPT | |
| SCHEMBL4771697 | 0.83 | ICAM1 (0.40) | ESR1HPGDNPSR1RXFP1 | |
| SCHEMBL4771921 | 0.83 | FGFR2 (0.41) | ESR1AKR1C3ALDH1A1MAPTNPSR1 | |
| SCHEMBL4770066 | 0.83 | ESR1 (0.40) | ESR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636213-B1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER LAMBERT CO (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1636213-A1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | BRUENDL MICHELLE M (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108715-A1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | MALT1, CYP1B1, CYP4B1 | PTGS2 412/4885PTGS1 101/4885ATM 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.